Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Protagonist Therapeutics, Inc. (PTGX : NSDQ)
 
 • Company Description   
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Number of Employees: 118

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.92 Daily Weekly Monthly
20 Day Moving Average: 1,948,384 shares
Shares Outstanding: 48.66 (millions)
Market Capitalization: $385.36 (millions)
Beta: 2.60
52 Week High: $50.54
52 Week Low: $7.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -58.12% -54.14%
12 Week -67.66% -63.65%
Year To Date -76.84% -71.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7707 GATEWAY BLVD. SUITE 140
-
NEWARK,CA 94560
USA
ph: 510-474-0170
fax: -
ir@ptgx-inc.com http://www.protagonist-inc.com
 
 • General Corporate Information   
Officers
Dinesh V. Patel - President; Chief Executive Officer and Director
Harold E. Selick - Chairman
Don Kalkofen - Chief Financial Officer
Bryan Giraudo - Director
Sarah Noonberg - Director

Peer Information
Protagonist Therapeutics, Inc. (CORR.)
Protagonist Therapeutics, Inc. (RSPI)
Protagonist Therapeutics, Inc. (CGXP)
Protagonist Therapeutics, Inc. (BGEN)
Protagonist Therapeutics, Inc. (GTBP)
Protagonist Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74366E102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 48.66
Most Recent Split Date: (:1)
Beta: 2.60
Market Capitalization: $385.36 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.99 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.26 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.28
Price/Cash Flow: -
Price / Sales: 8.22
EPS Growth
vs. Year Ago Period: 20.37%
vs. Previous Quarter: 44.16%
Sales Growth
vs. Year Ago Period: 315.61%
vs. Previous Quarter: 198.50%
ROE
03/31/22 - -38.01
12/31/21 - -40.29
09/30/21 - -35.08
ROA
03/31/22 - -33.25
12/31/21 - -35.29
09/30/21 - -30.72
Current Ratio
03/31/22 - 7.86
12/31/21 - 7.74
09/30/21 - 8.37
Quick Ratio
03/31/22 - 7.86
12/31/21 - 7.74
09/30/21 - 8.37
Operating Margin
03/31/22 - -261.21
12/31/21 - -458.94
09/30/21 - -440.88
Net Margin
03/31/22 - -261.21
12/31/21 - -458.94
09/30/21 - -440.88
Pre-Tax Margin
03/31/22 - -261.21
12/31/21 - -458.94
09/30/21 - -440.88
Book Value
03/31/22 - 6.20
12/31/21 - 6.29
09/30/21 - 6.91
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©